PHKG1(PHKg1)
Sign in to save this workspaceUniProt Q16816 · PDB · AlphaFold · Substrate: ZIPtide · Clone: full lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 100.0% | 0.0% | 78.64 | 0.500 |
| 2 | Brigatinib | 96.1% | 3.9% | 82.96 | 0.513 |
| 3 | Sunitinib | 95.6% | 4.4% | 91.73 | 0.524 |
| 4 | Alectinib | 94.5% | 5.5% | 95.49 | 0.651 |
| 5 | Abemaciclib | 91.4% | 8.6% | 91.48 | 0.563 |
| 6 | Ceritinib | 90.1% | 9.9% | 95.44 | 0.618 |
| 7 | Gilteritinib | 88.7% | 11.3% | 88.97 | 0.506 |
| 8 | Bosutinib | 82.5% | 17.5% | 87.22 | 0.555 |
| 9 | Repotrectinib | 78.8% | 21.2% | 84.21 | 0.608 |
| 10 | Pacritinib | 67.6% | 32.4% | 88.64 | 0.452 |
| 11 | Fedratinib | 66.6% | 33.4% | 96.21 | 0.576 |
| 12 | Lorlatinib | 64.7% | 35.3% | 97.24 | 0.694 |
| 13 | Afatinib | 54.8% | 45.2% | 98.50 | 0.709 |
| 14 | Vandetanib | 51.8% | 48.2% | 95.74 | 0.723 |
| 15 | Ruxolitinib | 45.4% | 54.6% | 98.25 | 0.592 |
| 16 | Gefitinib | 32.5% | 67.5% | 99.25 | 0.650 |
| 17 | Entrectinib | 32.2% | 67.8% | 93.69 | 0.671 |
| 18 | Dacomitinib | 30.2% | 69.8% | 97.99 | 0.664 |
| 19 | Rabusertib | 28.1% | 71.9% | 98.74 | 0.687 |
| 20 | Palbociclib | 28.0% | 72.0% | 98.75 | 0.673 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 0.84
- Epithelial log2(TPM+1): 0.88
- Fold change: -0.04
- Status: No significant change
High-confidence drugs
- Alectinib — inh 94.5% · KISS 36.63
- Ceritinib — inh 90.1% · KISS 35.51
- Midostaurin — inh 100.0% · KISS 30.19
Selectivity landscape vs inhibition on PHKG1
Each point is one of the 92 approved drugs; color = inhibition % on PHKG1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…